Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosis

P. L. Venturini, Pier Luigi Venturini, Venturini PL, Stefano Bertolini, Bertolini S, S Bertolini, M C Brunenghi, Maria Carla Marrè Brunenghi, Brunenghi MC, Daga A, A Daga, Antonio Daga, Vittorio Fasce, Fasce V, V. Fasce, Aldo Marcenaro, A Marcenaro, Marcenaro A, Maura Cimato, M Cimato, Cimato M, De Cecco L, L De Cecco, Luigi De Cecco
Fertility and sterility · 1989 · vol. 52(4) , pp. 589–95 · doi:10.1016/s0015-0282(16)60969-x · PMID:2806598
Other OA: closed public-domain-us
🔓 Open OA copy View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

Gestrinone treatment for 6 months reduced laparoscopic endometriosis scores and relieved pain in women, altering hormone levels and lipid profiles while demonstrating antiestrogenic, androgenic, and progestigenic effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The effect of oral gestrinone, 2.5 mg twice weekly for 6 months, was studied in 11 women with mild or moderate endometriosis laparoscopically confirmed. The mean laparoscopic score decreased from 17.18 to 9.09 (P greater than 0.005). Painful symptoms were relieved in all patients within 2 months from start of therapy. Gonadotropins, prolactin (PRL) 17 beta-estradiol (17 beta-E2), estrone (E1), progesterone (P), androstenedione (A), and dehydroepiandrosterone sulfate (DHEA-S) remained in the follicular phase range. Total testosterone (TT) and sex hormone-binding globulin (SHBG) decreased, whereas free testosterone (FT) slightly increased. Metabolic studies showed a decrease of total triglycerides, very low-density lipoprotein (VLDL) triglycerides, and high-density lipoprotein (HDL) and VLDL cholesterol, parallel to the decrease of associated apoproteins. Low-density lipoprotein cholesterol and apoprotein B increased during therapy. The results suggest that gestrinone possesses antiestrogenic, androgenic, and progestigenic effects at therapeutic dosages both by acting on central and peripheral steroid receptors. For its efficacy and good tolerance, gestrinone may be considered an option for treating endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endocrine Glands Endometriosis Gestrinone Norpregnatrienes Adult Adult Apoproteins Apoproteins Apoproteins Endocrine Glands Endocrine Glands Endometriosis Endometriosis Endometriosis Endometriosis Female Female Gestrinone Gestrinone Gonadal Steroid Hormones

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (19)

Cited by (1)

Source provenance

crossref
last seen: 2026-09-24T06:17:12.585820+00:00
europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
pubmed
last seen: 2026-10-08T21:19:08.299311+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine